CATEGORIES: CMT Update | Research

New Collaboration with the University of North Carolina at Chapel Hill and The Jackson Laboratory Addresses Charcot-MarieTooth/Inherited Neuropathy Mutations Using Gene Therapy

by | Apr 24, 2017 | 3 comments

Gene therapy represents an exciting new frontier being explored for treating a number of diseases. Currently, gene therapy is being used in a clinical trial to treat one of the rare forms of inherited neuropathy (IN), giant axonal neuropathy (GAN). Because of the potential gene therapy holds for treating a range of CMT/IN mutations-including the rarer ones—HNF is excited to announce a collaboration with the University of North Carolina at Chapel Hill and The Jackson Laboratory to begin the development of gene therapy approaches for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN). 

To start, our initial gene therapy work will focus on CMT type 6, which is caused by a recessive mutation in the C12orf65 gene and for which there is currently no treatment. CMT type 6 presents in patients with many of the typical symptoms associated with most types of CMT, but usually includes additional, significant impacts on vision and breathing that further challenge a patient’s quality of life.  And, unlike other forms of CMT, CMT type 6 is ultimately fatal. 

The CMT type 6 research that HNF is funding aims to replace the nonfunctional gene with a working copy.  Dr. Robert Burgess, lead co-investigator for this project, has developed a CMT type 6 mouse model to conduct a proof of concept study to determine the viability of using this approach to treat the disease. Dr. Steven Gray, assistant professor at the University of North Carolina, will be developing the gene therapy vector to be tested using this unique mouse model.  We are pleased to have Dr. Gray on this project’s team as his previous work was responsible for bringing the GAN gene therapy to a clinical trial.  Ensuring the success of this gene therapy approach will depend on getting everyone—health care providers and  CMT type 6 patients and their families— involved! Besides the work in the CMT type 6 mouse, patient specimens are extremely valuable for research. HNF will need to obtain skin fibroblasts from CMT type 6 patients that have a confirmed diagnosis. HNF will rely on its Centers of Excellence network and other medical institutions to obtain the skin fibroblasts needed to be sent to The Jackson Laboratory for further testing. 

Advancing a research project like this is a major undertaking requiring significant human, physical, and financial resources— however, the possibilities of achieving significant outcomes are unprecedented. To secure the ability of this project’s momentum, HNF has launched the Gene Therapy Fund to support this project’s efforts to tackle additional types of CMT/IN that warrant a gene therapy approach to treat CMT. The Gene Therapy Fund will be used and supported with the collaboration of Lori Sames (co-founder of Hannah’s Hope Fund and the tireless champion of the first gene therapy ever used for any  form of IN), UNC and The Jackson Laboratory.

We need your help! Here’s how to get involved: I support gene therapy research, and I want to enroll as a patient! If you are a patient with CMT and want to be part of this new initiative, please join the Global Registry for Inherited Neuropathies (GRIN). If you have any type of CMT/IN or do not know your type, join here: CLICK HERE

If you are interested in having your mutation added  to the list or in championing a gene therapy approach for  your type of CMT/IN, please contact Allison Moore at [email protected].

I support gene therapy research, and I want to make  a donation!

Your donations are crucial to making this research possible.

PLEASE DONATE TODAY

Learn more on this topic

Related Blog Posts

Collaboration is the Key to HNF Success

Collaboration is the Key to HNF Success

We at HNF are so proud of the accomplishments of those scientists we fund and are asking you to please continue to support our efforts. Our Therapeutic Research In Accelerated Discovery (TRIAD) program is a proven collaborative model in the drug discovery process.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

In Memoriam

The HNF family has lost two great people this summer: Franklin G. Downing Sr. (father of board member Matthew Downing) and George G. Gatta (father of board member Kathleen Zappola).

Join the conversation

Leave a Comment

3 Comments

  1. Barry Huffman

    I have CMT but not sure what level. I live in the Raleigh, NC area and would be interested in trial at UNC. I have issues with atrophy in my lower legs, hands and vision.

    Reply
  2. Margaret

    I have cmt 1b and live near Chapel Hill. I lead a large group of individuals with cmt. Great news!

    Reply
  3. Leon M Wallace

    I have CMT, but do not know what type. I wear a brace for drop foot on my left leg. My left leg is significantl smaller than my right leg. I also have significant balance issues. I cannot stand on my toes and I walk on the heels of both feet.

    I would like to have my mutation considered. I am 75 year of age and first noticed symptoms about fifteen years ago when I first noticed that I was unable to stand on my toes.

    I would like to participate in the clinical trial if possible.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news